Drugs in Dev. Infections and Infectious Diseases
Phase I
Denmark 
Lead Product(s) : MVA-BN
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : CEPI
Deal Size : $6.5 million
Deal Type : Partnership
Bavarian Nordic and CEPI Partners to Advance Mpox Vaccination in Africa
Details : The partnership aims to advance the development of Bavarian Nordic’s mpox vaccine, MVA-BN or Modified Vaccinia Ankara-Bavarian Nordic, a non-replicating vaccine, in children in Africa.
Product Name : MVA-BN
Product Type : Vaccine
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : MVA-BN
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : CEPI
Deal Size : $6.5 million
Deal Type : Partnership
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : CARB-X
Deal Size : $5.4 million
Deal Type : Funding
SNIPR Biome Receives CARB-X Funding to Advance SNIPR001 in Haematological Cancers
Details : Funding supports SNIPR Biome’s CRISPR-medicine SNIPR001, undergoing early-stage trials for E. coli bloodstream infections in patients with hematological cancers.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : CARB-X
Deal Size : $5.4 million
Deal Type : Funding
Lead Product(s) : FB-101
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FB101, is an investigational vaginal microbial immunotherapeutic, which is investigated for the treatment of Women with Asymptomatic Vaginal Dysbiosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : FB-101
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBS-NN/NN2,GBS/NN2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : European and Developing Countries Clinical Trials Partnership
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GBS-NN/NN2 is a novel innovative, adjuvanted protein Vaccine which are based on traditional capsular polysaccharide (CPS) conjugate technology and investigated for the treatment of Group B Streptococcus.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 27, 2023
Lead Product(s) : GBS-NN/NN2,GBS/NN2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : European and Developing Countries Clinical Trials Partnership
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SNIPR001 is a novel, first-in-human, CRISPR-based microbial gene therapy, developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
May 31, 2023
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GBS-NN/NN2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GBS-NN/NN2 Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Streptococcal Infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 23, 2023
Lead Product(s) : GBS-NN/NN2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : IQVIA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MVA-BN-WEV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : US Department of Defense
Deal Size : $83.0 million
Deal Type : Agreement
Details : MVA-BN WEV, a prophylactic vaccine candidate, is a multi-valent vaccine candidate since it incorporates antigens from all three equine encephalitis viruses: western, eastern and Venezuelan.
Product Name : MVA-BN-WEV
Product Type : Vaccine
Upfront Cash : Undisclosed
December 23, 2022
Lead Product(s) : MVA-BN-WEV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : US Department of Defense
Deal Size : $83.0 million
Deal Type : Agreement
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SNIPR Biome Further Strengthens CRISPR/Cas IP Portfolio With Patent Grant
Details : SNIPR’s CRISPR technology provides a highly selective way to target individual bacterial strains for killing which can be useful for the prevention and treatment of any indication where a specific bacterial strain is the underlying cause of a disease.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
December 22, 2022
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SNIPR001, is the first orally dosed CRISPR-based therapeutic candidate and CRISPR-armed bacteriophage cocktail that targets antibiotic-resistant E. coli infections in hematological cancer patients.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
October 03, 2022
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SNIPR Biome Granted New US Patent Covering Lytic CRISPR Phage
Details : SNIPR001, a CRISPR-armed bacteriophage cocktail that targets the prevention of antibiotic-resistant E. coli infections in hematological cancer patients.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
August 02, 2022
Lead Product(s) : SNIPR001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
